Company:  ALIMERA SCIENCES INC (ALIM)
Form Type:  10-Q
Filing Date:  11/7/2011 
CIK:  0001267602 
Address:  6120 WINDWARD PARKWAY
STE 290
 
City, State, Zip:  ALPHARETTA, Georgia 30005 
Telephone:  (678) 990-5740 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.14  
Change: 
0.03 (0.49%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$247.45M
Description of Business
Alimera Sciences, Inc., and its subsidiaries (we, Alimera or the Company), is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity. Our only commercial product is ILUVIEN�, which has received marketing authorization in Austria, the United Kingdom, Portugal, France, Germany and Spain, and has been recommended for marketing authorization in Italy, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1 Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
      ITEM 2 Management's Discussion and Analysis of Financial ...
      ITEM 3 Qualitative and Quantitative Disclosures about ...
    PART II. OTHER INFORMATION
      ITEM 1A Risk Factors
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
  EXHIBIT 31.2
    CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
  EXHIBIT 32.1
    Certification
BROKERAGE PARTNERS